Author:
Cornud F.,Delongchamps N. B.,Mozer P.,Beuvon F.,Schull A.,Muradyan N.,Peyromaure M.
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Afaq A, Koh DM, Padhani A, van As N, Sohaib SA. Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. BJU Int. 2011 Jun 1
2. D’Amico AV, Renshaw AA, Cote K, Hurwitz M, Beard C, Loffredo M, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(18):3726–32.
3. • Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20;27(21):3459–64. For prostatectomy specimens, 4 + 3 cancers were associated with a threefold increase in lethal prostate cancer compared with 3 + 4 cancers. This important finding has led to classify tumors with a Gleason score 7, 4 + 3 on TRUS-guided biopsies in the high-risk group.
4. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 1998;160(6 Pt 2):2407–11.
5. • Lawrentschuk N, Haider MA, Daljeet N, Evans A, Toi A, Finelli A, et al. ‘Prostatic evasive anterior tumours’: the role of magnetic resonance imaging. BJU Int. 2010 May;105(9):1231–6. This is one of the first papers to suggest that tumor burden of anterior tumors was commonly underestimated by a standard 12 posterior core sextant biopsy protocol.
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献